Histogen rises on agreement with Johns Hopkins University

Histogen

03/04/2023 22:42

** Shares of drug developer Histogen Inc  HSTO.O  rise ~5%
to $1.25
    ** Announces exclusive intellectual property license
agreement with Johns Hopkins University for product candidate
emricasan
    ** Says license covers use of emricasan for treatment of
viral or bacterial infections 
    ** HSTO anticipates initiation of clinical development using
emricasan for treatment of acute bacterial skin and skin
structure infections in H2 
    ** Adds licensed patents expected to provide freedom to
operate and exclusivity for emricasan
    ** Stock up ~43% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))